RxDoctor Payments DataLook up a doctor →

Ji Han, MD

Interventional Pain Medicine · Flushing, NYNPI 1801937750

Payments from drug & device makers

$14,184in general payments, 2019–2025

Across 458 payments — averaging $30.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Scilex Pharmaceuticals Inc.$1K
  • Redhill Biopharma Inc.$1K
  • Boston Scientific$786
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$783
  • Medtronic$611
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$8306%
  • Travel & lodging$7866%
  • Food & beverage$12,56889%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,184 in reported general payments places this provider in the 80th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$732,991
Medicare patients
371
Services billed
13,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZtlidoLidocaine308$171,666
Diclofenac Epolamine150$99,898
OxycontinOxycodone Hcl27$71,394
MovantikNaloxegol Oxalate156$60,744
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen916$45,313
Lidocaine177$27,320
RelistorMethylnaltrexone Bromide15$24,214
Diclofenac Sodium248$22,896
Doxepin Hcl109$18,379
Pregabalin430$13,717
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)273$12,604
Piroxicam80$12,104
Oxycodone Hcl580$9,771
Gabapentin1,005$9,179
Fluocinonide55$8,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$1,346$171,666308 claims
Redhill Biopharma Inc.Movantik$1,074$60,744156 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$783$24,21415 claims
Collegium Pharmaceutical, Inc.Xtampza Er$431$8,09616 claims
Shionogi IncSymproic$77$6,42515 claims
Hikma Pharmaceuticals USAMorphine Sulfate$22$1,25137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 132 interventional pain medicine providers in New York.

Other interventional pain medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →